Results 161 to 170 of about 12,522 (211)

Caspofungin enhances antifungal immunity in human blood through transcriptional reprogramming. [PDF]

Microlife
Shehata A, Schäuble S, Martin R, Aldejohann AM, Panagiotou G, Kurzai O, Hünniger-Ast K.   +6 more
europepmc   +1 more source

Echinocandins in invasive candidiasis [PDF]

Mycoses, 2013
SummaryWe summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managingIC. The echinocandins have demonstrated good activity against non‐albicansinfections and also azole‐resistant strains, both preclinically and in recent clinical trials.
George Dimopoulos, Hsin-Yun Sun
exaly   +5 more sources

Echinocandins as Biotechnological Tools for Treating Candida auris Infections [PDF]

Journal of Fungi (Basel, Switzerland), 2020
Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of ...
Marlon Cardoso, Octavio Franco, Elizabete De Souza Cândido   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The Echinocandins

Pharmacotherapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty, Kasi, Eiselstein-McKitrick   +1 more
exaly   +3 more sources

Echinocandins in Children

Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire   +4 more sources

In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris [PDF]

Antibiotics, 2021
Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs.
Valvanera Vozmediano, Stephan Schmidt, Sarah Kim-Mcolash   +2 more
exaly   +3 more sources

Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance [PDF]

International Journal of Infectious Diseases, 2020
Introduction: A possible increase in Candida resistance, especially in Candida glabrata, has been speculated according to poor diffusion of echinocandins to peritoneal fluid.
Santiago Moreno, Jesus Fortun, Pilar Martín-Dávila   +2 more
exaly   +3 more sources

Echinocandins in Ocular Therapeutics

Journal of Ocular Pharmacology and Therapeutics, 2017
Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash, Patil, Soumyajit, Majumdar
openaire   +2 more sources

Micafungin - The newest echinocandin

Drugs of Today, 2009
Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem, Temesgen, Jason, Barreto, Sandro, Vento   +2 more
openaire   +2 more sources